Hormonal
Performing bariatric surgery (Roux-en-Y or sleeve gastrectomy) prior to abdominoplasty significantly reduces postoperative complications and improves long-term stability compared to abdominoplasty alone in patients with metabolic syndrome.
If you have significant excess abdominal skin and metabolic issues (high blood pressure, diabetes, or high cholesterol), do not rush into skin removal surgery. You must first lose weight through diet, medication (like GLP-1s), or bariatric surgery until your weight and metabolic markers are stable for at least 6-12 months. This sequence drastically lowers your risk of infection, blood clots, and poor scarring, and ensures the skin removal looks good long-term.
Так, тільки після застосування консервативних чи хірургічних методів лікування, при досягненні задовільного результату зниження маси тіла та компенсації чи покращення перебігу МС пацієнтам з естетичною деформацією передньої черевної стінки... слід розглядати естетичну хірургічну корекцію — абдомінопластику. Цей підхід забезпечує мінімальний ризик розвитку післяопераційних ускладнень після абдомінопластики, максимальну ефективність та безпеку.
Why this rating
The paper cites large cohort studies (SOS study) and meta-analyses supporting bariatric efficacy, though it is a review article rather than a primary RCT of the combined procedure.
Source
Comprehensive approach to the treatment of patients with aesthetic deformity of the anterior abdominal wall with concomitant metabolic disorders
Todurov et al. · Diabetes Obesity Metabolic Syndrome · 2025
DOI 10.57105/2415-7252-2025-4-03
More from this paper
- GLP-1 receptor agonists (e.g., Semaglutide) are effective for weight loss and metabolic stabilization but cause significant weight regain (rebound) upon discontinuation, necessitating long-term management or transition to surgery.Strong
- Bariatric surgery (Roux-en-Y or Sleeve Gastrectomy) provides superior long-term weight loss and metabolic remission compared to conservative lifestyle interventions alone.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →